Literature DB >> 19706628

Global drug discovery: Europe is ahead.

Donald W Light1.   

Abstract

It is widely believed that the United States has eclipsed Europe in pharmaceutical research productivity. Some leading analysts claim that although fewer drugs have been discovered worldwide over the past decade, most are therapeutically important. Yet a comprehensive data set of all new chemical entities approved between 1982 and 2003 shows that the United States never overtook Europe in research productivity, and that Europe in fact is pulling ahead of U.S. productivity. Other large studies show that most new drugs add few if any clinical benefits over previously discovered drugs. I discuss ways in which Congress, employers, and insurers can increase the value of drugs and revitalize the U.S. pharmaceutical industry.

Mesh:

Year:  2009        PMID: 19706628     DOI: 10.1377/hlthaff.28.5.w969

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  9 in total

1.  Location of pharmaceutical innovation: 2000-2009.

Authors:  Yali Friedman
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 2.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

3.  The nature of Asian biopharmaceutical innovation.

Authors:  Yali Friedman
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908

4.  Measuring the efficiency of large pharmaceutical companies: an industry analysis.

Authors:  Fernando Gascón; Jesús Lozano; Borja Ponte; David de la Fuente
Journal:  Eur J Health Econ       Date:  2016-06-25

Review 5.  Animal models for exploring the pharmacokinetics of breast cancer therapies.

Authors:  Omar M Rashid; Kazuaki Takabe
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-11-21       Impact factor: 4.481

6.  An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access.

Authors:  Amy V Jones; Darin Curtiss; Claire Harris; Tom Southerington; Marco Hautalahti; Pauli Wihuri; Johanna Mäkelä; Roosa E Kallionpää; Enni Makkonen; Theresa Knopp; Arto Mannermaa; Erna Mäkinen; Anne-Mari Moilanen; Tongalp H Tezel; Nadia K Waheed
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

7.  An improved syngeneic orthotopic murine model of human breast cancer progression.

Authors:  Omar M Rashid; Masayuki Nagahashi; Suburamaniam Ramachandran; Catherine Dumur; Julia Schaum; Akimitsu Yamada; Krista P Terracina; Sheldon Milstien; Sarah Spiegel; Kazuaki Takabe
Journal:  Breast Cancer Res Treat       Date:  2014-09-09       Impact factor: 4.872

8.  A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer.

Authors:  O M Rashid; D Maurente; K Takabe
Journal:  Chemotherapy (Los Angel)       Date:  2016-05-30

9.  Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation.

Authors:  Yi Zhang; Gan-Lin Zhang; Xu Sun; Ke-Xin Cao; Cong Ma; Nan Nan; Guo-Wang Yang; Ming-Wei Yu; Xiao-Min Wang
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.